Journal
INTERNAL MEDICINE
Volume 60, Issue 24, Pages 3991-3993Publisher
JAPAN SOC INTERNAL MEDICINE
DOI: 10.2169/internalmedicine.6723-20
Keywords
progressive multifocal leukoencephalopathy; ofatumumab; chronic lymphocytic leukemia
Categories
Funding
- JSPS KAKENHI [17K09768]
- Research Committee of Prion Disease and Slow Virus Infection, Research on Policy Planning and Evaluation for Rare and Intractable Diseases, Health and Labour Sciences Research Grants, The Ministry of Health, Labour and Welfare, Japan
- Grants-in-Aid for Scientific Research [17K09768] Funding Source: KAKEN
Ask authors/readers for more resources
A 79-year-old man developed progressive multifocal leukoencephalopathy during ofatumumab therapy for refractory chronic lymphocytic leukemia, and unfortunately passed away despite treatment.
A 79-year-old man experienced cognitive impairment and visual field defects during ofatumumab therapy for chronic lymphocytic leukemia refractory to combination chemotherapy. Magnetic resonance imaging revealed T1-weighted low-intensity and T2-weighted high-intensity lesions with patchy gadolinium enhancement in the subcortical white matter. A diagnosis of progressive multifocal leukoencephalopathy was mad after the detection of John Cunningham virus (JCV) DNA in his cerebrospinal fluid (CSF). Following plasma exchange and the administration of mirtazapine and mefloquine, the JCV DNA levels in the CSF decreased. However, the patient died 55 days after treatment was initiated. Ofatumumab treatment appears to be associated with the development of progressive multifocal leukoencephalopathy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
